Would you use OncoType in a postmenopausal female with HR+/HER2- with LN involvement who clinically meets RxPONDER criteria of 1-3 LN to guide the use of neoadjuvant chemotherapy?
How would the use of Oncotype guide your management in the neoadjuvant setting?
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Duke University
Answered on
Yes. If I am asked to consider neoadjuvant therapy in a postmenopausal woman with an ER/PR+, HER2 negative cancer, who is otherwise a candidate for chemotherapy, I will start the endocrine therapy and send OncotypeDX to make sure that we are not leaving out an important part of her management, i.e. ...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
Answered on
I am not sure if I would. Having seen unimpressive results on my patients I've enrolled on ALTERNATE trial and the unimpressive preliminary results of the ALTERNATE trial, I believe neoadjuvant approach is not as promising as it is in HER-2 positive or triple negative breast cancer setting.
Join for free or sign in to see the full answer